From GlobeNewswire: 2025-03-03 01:30:00

Exosens exceeded IPO guidance with a +35.0% revenue growth to €394.1m in 2024, boasting an adjusted EBITDA of €118.5m (+37.8%). Net profit surged to €30.7m, with a strong balance sheet and proposed dividend of €0.10 per share. Expansion plans include a new production plant in the US to meet increased demand.

The outlook for 2025 anticipates high-teens revenue growth and low twenties EBITDA growth, driven by defense market tailwinds. Exosens plans to invest €20m in capacity expansion in Europe and the US to capitalize on market opportunities, building on its strong performance in 2024.

Exosens, a high-tech company, reported a significant revenue increase in FY 2024, driven by demand in Defense markets. Amplification revenue grew by +33.5%, while Detection & Imaging revenue increased by +42.5%. Major business wins in key markets like Germany and the UK solidified Exosens’ position as the strategic supplier for night vision systems.

The company’s strong financial performance in FY 2024 was underpinned by a robust balance sheet, improved profitability, and significant growth in net income. Free cash flow rose to €55.4m, with a cash conversion rate of 74.1%. R&D investments and capacity expansion further support Exosens’ long-term growth strategy.



Read more at GlobeNewswire:: Exosens delivers very strong full-year 2024 results,